Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Hematologic Neoplasms 1 Hematologic Diseases 1

Interventions

Carboplatin 15 camrelizumab 11 Capecitabine 11 130-nm albumin-bound paclitaxel 10 pembrolizumab 8 eribulin 8 Paclitaxel 8 Cyclophosphamide 7 Gemcitabine 6 Epirubicin 6 Cisplatin 6 apatinib 5 tislelizumab 4 atezolizumab 4 anlotinib 4 Taxes 4 Nivolumab 4 Docetaxel 4 Bevacizumab 4 Vinorelbine 3 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3 Doxorubicin 3 toripalimab 2 talazoparib 2 spartalizumab 2 olaparib 2 fluzoparib 2 famitinib 2 Zoledronic Acid 2 Metformin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Triple Negative Breast Neoplasms × AC protocol × Clear all

NCT04248998 2023-01-18

BREAKFAST

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Unknown

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡